A Pilot Dose Ranging Study of Dysport (AbobotulinumtoxinA) in the Treatment of Oromandibular Dystonia
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Dystonia
- Focus Therapeutic Use
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 28 Apr 2017 Results assessing the efficacy and safety of botulinum toxin A [Dysport, abobotulinumtoxinA] in patients with oromandibular dystonia, presented at the 69th Annual Meeting of the American Academy of Neurology.